Compare Cassava Sciences Inc (FLNA) vs FTAI Aviation Ltd (FTAI) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

FTAI Aviation trades at $174.83, down 2.57% with a bearish technical signal despite unanimous analyst buy ratings. The company reported strong revenue growth to $2.51B in 2025 but missed Q2 2026 EPS estimates. Recent developments include a $500M share repurchase program and acquisition of 27 Boeing 737-700 aircraft, signaling strategic expansion in aerospace services.

FTAI presents a compelling growth story with 100% analyst buy consensus and $321.25 price target, but faces execution risks from negative operating cash flow and earnings misses. The transition to fee-based management and aerospace expansion offers upside potential, though high valuation multiples and cash flow concerns warrant caution.